Stellate Ganglion Block to Treat Long COVID 19 Case Series

Metamorphosis LTD41 enrolled

Overview

An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.

We evaluated the treatment results of 41 patients (18 male and 23 female) aged between 18 and 89, who received Stellate Ganglion Block (SGB) with Ultrasound guidance for Long COVID-19 Syndrome. The patients were from the United States and received treatment at our Colorado clinics during the period of September to December 2022.Those who responded to our post-procedure follow-up calls were included in the study population.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Long COVID Long Covid19 Post-COVID-19 Syndrome Post Acute COVID-19 Syndrome Dysautonomia Anosmia Dysgeusia Brain Fog

Interventions

Stellate Ganglion BlockPROCEDURE

Ultrasound guided block of the Stellate Ganglion with local anesthetics.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: People who scheduled themselves for a SGB in our clinics in Colorado. \- Exclusion Criteria: Stellate Ganglion Block Contraindications \-

Locations (1)

Metamorphosis LTD

Cañon City, Colorado, United States

Outcomes

Primary Outcomes

Symptom Response

Evaluation of the symptoms response to the Stellate Ganglion Block

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.